Webinar: Harnessing Anti-Cytomegalovirus Immunity for Local Immunotherapy Against Solid Tumors
John Schiller, Ph.D., Deputy Chief of the NCI CCR Laboratory of Cellular Oncology
December 15, 2022 | 10:00 AM – 11:00 AM
Online
Deputy Chief of the NCI CCR Laboratory of Cellular Oncology, John Schiller, Ph.D. presents a new immunotherapy method targeting solid tumors.
This invention involves the injection of cytomegalovirus- (CMV) derived T cell minimal peptide epitopes into a solid tumor, disrupting the tumor microenvironment and allowing CD4+ and CD8+ T cells to kill the tumor cells and the generation of T cells to tumor-restricted antigens.
The tumor antigen-agnostic nature of this approach makes it applicable across a broad range of solid tumors, regardless of origin.
The results of his work show that CMV-derived peptide epitopes, delivered intratumorally into mice with chronic mouse CMV infections, act as cytotoxic and immunotherapeutic agents to promote immediate tumor control and long-term antitumor immunity. This technology can be used as a stand-alone therapy.
Request the Recording
Please reach out to Joseph.Conrad@nih.gov to request the recording, or if you have interest in learning about co-development and/or licensing opportunities for this technology.